---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026708"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:48:32.798231+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal

## Summary
- Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.
- Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.
- Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.
- Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.
- No assurance that Company will ultimately regain compliance and remain listed on Nasdaq.

## SEC filing metadata
- accession: 0001104659-25-026708
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/0001104659-25-026708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/tm259958d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026708
- JSON: https://secwatch.observer/filing/0001104659-25-026708.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.